Chromadex Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US1710774076
USD
6.70
0.3 (4.69%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Chromadex Corp. stock-summary
stock-summary
Chromadex Corp.
Pharmaceuticals & Biotechnology
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.
Company Coordinates stock-summary
Company Details
10900 Wilshire Blvd Ste 600 , LOS ANGELES CA : 90024-6534
stock-summary
Tel: 1 310 38867061 949 4190288
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 33 Schemes (10.66%)

Foreign Institutions

Held by 33 Foreign Institutions (3.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Frank Jaksch
Executive Chairman of the Board
Mr. Robert Fried
Chief Executive Officer, Director
Mr. Kurt Gustafson
Lead Independent Director
Mr. Jeffrey Baxter
Independent Director
Mr. Stephen Block
Independent Director
Mr. Tony Lau
Independent Director
Mr. Steven Rubin
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
31 Million
(Quarterly Results - Jun 2025)
Net Profit:
4 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 754 Million (Micro Cap)

stock-summary
P/E

63.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.93

stock-summary
Return on Equity

29.49%

stock-summary
Price to Book

11.74